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Abstract
White matter (WM) disease is associated with disruption of the gliovascular unit, 
which involves breach of the blood–brain barrier (BBB). We quantified pericytes as 
components of the gliovascular unit and assessed their status in vascular and other 
common dementias. Immunohistochemical and immunofluorescent methods were 
developed to assess the distribution and quantification of pericytes connected to the 
frontal lobe WM capillaries. Pericytes with a nucleus were identified by collagen 4 
(COL4) and platelet-derived growth factor receptor-β (PDGFR-β) antibodies with 
further verification using PDGFR-β-specific ELISA. We evaluated a total of 124 
post-mortem brains from subjects with post-stroke dementia (PSD), vascular dementia 
(VaD), Alzheimer’s disease (AD), AD-VaD (Mixed) and post-stroke non-demented 
(PSND) stroke survivors as well as normal aging controls. COL4 and PDGFR-β 
reactive pericytes adopted the characteristic “crescent” or nodule-like shapes around 
capillary walls. We estimated densities of pericyte somata to be 225 ±38 and 200 ±13 
(SEM) per COL4 mm2 area or 2.0  ±  0.1 and 1.7  ±  0.1 per mm capillary length 
in young and older aging controls. Remarkably, WM pericytes were reduced by 
~35%–45% in the frontal lobe of PSD, VaD, Mixed and AD subjects compared to 
PSND and controls subjects (P  <  0.001). We also found pericyte numbers were 
correlated with PDGFR-β reactivity in the WM. Our results first demonstrate a 
reliable method to quantify COL4-positive pericytes and then, indicate that deep 
WM pericytes are decreased across different dementias including PSD, VaD, Mixed 
and AD. Our findings suggest that downregulation of pericytes is associated with 
the disruption of the BBB in the deep WM in several aging-related dementias.
INTRODUCTION
Older age is identified as the single most important risk fac-
tor contributing to increased white matter hyperintensities 
(WMH) on T2-weighted magnetic resonance imaging. Increased 
volumes of WMHs are associated with vascular disease, dis-
ability, cognitive impairment and death (17, 24, 34, 41). WMHs 
have been largely attributed to cerebral small vessel disease 
(SVD) but large vessel disease may also contribute to WM 
lesions (5, 17, 32). We have previously identified the cell and 
molecular changes within the gliovascular unit that incorporates 
the blood–brain barrier (BBB) in the deep frontal WM of 
elderly patients who develop dementia after stroke (13, 30). 
Perivascular astrocytic degeneration characterized by clasma-
todendrosis was a key feature associated with stroke survivors 
who developed dementia relative to those who remained cog-
nitively intact. However, it is unknown how other key cellular 
components of the gliovascular unit such as pericytes are 
affected in stroke survivors or those who develop vascular 
dementia (VaD).
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Pericytes function like mural cells on the capillary endothe-
lium, on precapillary arterioles and on postcapillary venules 
(7, 9, 10, 20). Multiple functions beyond contractile control 
of blood flow (26) are attributed to pericytes including par-
acrine signaling during angiogenesis and phagocytosis. 
Pericytes play an important role in BBB function (53). Pericyte 
coverage on brain capillaries in the mouse at least is esti-
mated to be >90% (9) that is characterized by longitudinal 
and circumferential processes around capillaries. The platelet-
derived growth factor (PDGF) is one of the key signaling 
pathways identified in pericytes (38). Endothelial PDGF-β 
recruits pericytes via the PDGF receptor-β (PDGFR-β) and 
disruption of PDGFR-β signaling results in fewer recruited 
pericytes to the vessel, causing vessel leakage, tortuosity, 
microaneurysms and microbleeds (12). In this context, we 
showed that bone morphogenetic protein-4 (BMP4) was highly 
expressed in WM pericytes in cerebral SVD (52). Chronic 
cerebral hypoperfusion upregulated BMP4 to promote angio-
genesis but induced astrogliogenesis at the expense of oli-
godendrocyte precursor cell proliferation and maturation, 
thereby aggravating WM damage.
The lack of  reliable markers of  pericytes had hampered 
their complete characterization (50). A reliable, robust 
method to identify and quantify pericytes would accelerate 
the research and deepen our understanding on the role 
of  pericyte in brain disorders. In this study, we used a 
simple reliable method to identify pericytes and determined 
their status across different neurocognitive disorders includ-
ing poststroke dementia (PSD), VaD, Alzheimer’s disease 
(AD) and mixed dementia with vascular and Alzheimer 
pathologies with the hypothesis that they are vulnerable 
in diffuse WM disease, which is one of  the signatures of 
SVD. In addition, we evaluated perfused post-mortem 
brain tissue from nonhuman primates subjected to cerebral 
hypoperfusion (13). We focused on pericytes because of 
their close relationship with endothelial cells (29) and they 
are key cellular components of  the gliovascular unit, which 
disintegrates during WM damage. We concentrated on the 
frontal lobe because of  its contiguity with the centrum 
semiovale region and its relative vulnerability in cerebro-
vascular diseases (35, 36).
MATERIALS AND METHODS
Subjects
Table 1 provides demographic details and diagnoses in 
124 subjects derived from our longitudinal prospective 
dementia series and aging controls. Dementia was clinically 
diagnosed and pathologically confirmed by post-mortem 
examination as either AD, mixed AD-VaD, (Mixed), VaD 
or PSD. Available radiological reports indicated WM 
changes consistent with SVD of  the brain in most dementia 
patients (31). In addition, we assessed poststroke no demen-
tia (PSND) subjects as well as young and older controls. 
The mean age of  the older controls was not different 
from any of  the dementia subjects. The controls, aged 
55–99  years were participants either in previous 
prospective studies or from unrelated brain donations to 
the Newcastle Brain Tissue Resource (NBTR). They were 
selected to be included as controls if  they had no cogni-
tive impairment or clinical or pathological evidence of 
neurological or psychiatric disease. The VaD, PSD and 
PSND subjects were from the Newcastle Cognitive Function 
after Stroke study (2). Local research ethics committees 
of  the Newcastle upon Tyne NHS Foundation Hospitals 
Trust granted ethical approvals. Permission to use brains 
for post-mortem research was also granted by consent 
from the individuals themselves when they had been still 
alive or next-of-kin or family member. All brain tissues 
were obtained from the NBTR.
Brain tissues and neuropathological analyses
Neuropathological assessment was carried out as described 
previously (32). Briefly, hematoxylin and eosin (H&E) stain-
ing was used for assessment of structural integrity and infarcts, 
Nissl and Luxol Fast blue staining for cellular patterns and 
myelin loss, Bielschowsky’s silver method and amyloid-β 
immunohistochemistry for ABC rating of neuritic plaques, 
Gallays stain for neuritic pathology and tau immunohisto-
chemistry for Braak staging of neurofibrillary tangles. The 
clinical diagnosis of AD was confirmed on evidence of sig-
nificant Alzheimer’s-type pathology incorporating Braak stages 
V–VI, moderate-severe CERAD (40) and high ABC scores 
per National Institute of Aging-Alzheimer’s Association 
guidelines (45) and an absence of significant vascular pathol-
ogy. The clinical diagnosis of VaD was made when there 
were multiple or cystic infarcts, lacunae, border-zone infarcts, 
microinfarcts and SVD and pathologically confirmed as Braak 
stage  ≤  IV (36, 37). Mixed AD and VaD case was classified 
when there was sufficient degree of AD pathology (45) and 
significant vascular pathology (Table 1).
Vascular pathology scores were derived from the presence 
of vascular lesions/pathologies as described previously (18). 
WM lesion (WML) scores were determined on scale of 0 
to 3 signifying none, mild, moderate and severe. Previously, 
we had shown there was 95% agreement in scoring between 
two assessors (18). WM/vascular lesion severity was graded 
from low to severe in quartiles essentially as described pre-
viously (33). All the vascular measures were compatible with 
the recently established vascular cognitive impairment neu-
ropathology consortium criteria (49). Tissues from control 
subjects had occasional aging-related pathology and were 
classified as “no pathological diagnosis” (Table 1). Except 
for neuropathological examination (RNK), all subsequent 
morphological analyses were undertaken under operator-
blinded conditions. Samples were identified with coded 
sequential numbers. In addition, at least two of both posi-
tive and negative controls were included to monitor the 
quality of staining.
Immunohistochemistry methods
Formalin-fixed paraffin-embedded whole coronal sections at 
levels 6–8 (36,48) containing the frontal lobe (Brodmann 
area 9) were analyzed. When sampling tissue, we ensured 
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to select the WM regions free of any obvious infarcts and 
thus assessed effects of remote stroke injury. Immuno-
histochemistry was performed to examine various microvas-
cular structures essentially as described before (16, 29). The 
following antibodies were used to assess various cellular 
features: collagen IV (COL4 at dilution 1:1000, C1926, Merck 
(Sigma-Aldrich), Branchburg, NJ, USA), a marker of base-
ment membrane in the vessels, platelet-derived growth factor 
receptor-β (PDGFR-β at 1:200 dilution, clone 42G12, #AF385, 
R&D systems, Minneapolis, MN, USA), a marker for peri-
cytes, bone morphogenetic protein 4 (BMP4 dilution at 1:100, 
MBA1049, Millipore, MA, USA), α-smooth muscle actin 
(αSMA at dilution 1:1000, Clone 1A4, Dako, Cambridge, 
UK), a marker for mural cells and glucose transporter-1 
(GLUT-1 at 1:200, PA1-21041, Fisher Scientific, Waltham, 
MA, USA), a marker of endothelial cells. Vectastain ABC 
mouse kits (PK-6102, Vector Laboratories, Burlingame, CA, 
USA) and DAB were used to localize single or double 
immunohistochemical stains. Tissue sections were then counter 
stained with hematoxylin to visualize the landmarks.
Electron microscopy
Post-mortem brain tissues from relevant controls were sam-
pled from the gray matter and WM for the temporal lobe. 
Subsequent to 16-h fixation in 2% paraformaldehyde and 
0.05% glutaraldehyde in 0.1 M phosphate buffer (PB, pH7.4), 
samples were rinsed in two changes of  PBS. Half  of  each 
batch of samples was treated with 1% osmium tetroxide 
(OsO4) in 0.1  M PB. Samples were dehydrated in increas-
ing concentrations of  alcohol, cleared in propylene oxide 
and then, embedded in epoxy resin. Sections were cut into 
1  μm using an Ultracut microtome (Reichert-Jung, Depew, 
NY) and stained with 1% Toluidine blue and 1% borax 
Table 1. Demographic details of all the cases and controls.
Variable Young controls Old controls PSND PSD VaD Mixed AD
N 12 20 21 20 17 18 16
Mean age, years 
(range)
57.5 (46–65) 79.3 (78–94) 85.1 (75–96) 87.1 (75–96) 84.2 (71–98) 85.1 (72–93) 84.2 (76–96)
Gender (M:F %) 55:45 35:65 57:43 30:70 41:59 44:56 56:44
MMSE, 
mean ± SEM
na 29 ± 1 27 ± 0.4 16 ± 1 13 ± 4 11 ± 2 7 ± 2
CAMCOG, 
mean ± SEM
na na 90 ± 1 66 ± 3 na na 39 ± 7
Braak stage, 
mean (range)
0.25 (0–1) 1.9 (0–4) 2.6 (1–4) 2.6 (1–4) 2.0 (0–4) 5.2 (5–6)‡ 5.6 (5–6)‡
CERAD, mean 
(range)
0.0 (0–0) 0.5 (0–2) 1.7 (1–2) 1.3 (1–3) 1.0 (0–2) 2.9 (2–3) ‡ 2.9 (2–3) ‡
ABC scores, 
mean
na A0.5, B1.2, C0.5 A0.5, B1.2, C0.7 A0.5, B1.2, C0.8 A0.6, B1.2, C0.8 A2.5, B2.6, 
C2.6
A3, B3, C3
CAA frequency 
(moderate-
severe), %
0 6 15 18 17 9 39
Vascular 
pathology 
score, mean 
(range)†
na 6.7 (0–10)† 13.5 (13–14) 13.3 (9–17) 13.2 (10–16) 11.0 (6–14) 10.8 (3–16)
WML score, 
mean (range)
na 0.5 (0–2)† 2.5 (2–3) 2.4 (2–3) 2.9 (2–3) 2.9 (2–3) 1.8 (0–3)
White matter/
vascular 
lesions, 
moderate-
severe (%)
na 17.6** 100 100 100 95 72
Numbers represent mean values (±SEM) and where given with the range of values in parentheses. The causes of death included bronchopneumonia 
(95%), cardiac arrest and carcinoma, renal failure and gastrointestinal bleed with no particular distribution pattern in any group. The post-mortem in-
terval between death and tissue retrieval ranged 24–47 h for all the cases. There were no differences in the length of post-mortem delay between 
groups. Braak staging scores and Alzheimer’s disease neuropathologic changes (45) were different in mixed and AD cases compared to all other 
groups (P < 0.05). Mean vascular pathology scores (range) for PSND and PSD groups were 13.5 (13–14) and 13.3 (9–17) compared to 6.7 (0–10) for 
controls (†P < 0.05). These scores were derived as described previously (18). WML Score, white matter pathology score assessed using scale from 
(18). Mean WML Score was high in all poststroke and dementia subjects compared to controls (†P < 0.01). WM/Vascular lesions, **P < 0.01 compared 
to all poststroke and dementia subjects.
Abbreviations: ABC = AD Neuropathology scoring system; AD = Alzheimer’s disease; CAA = cerebral amyloid angiopathy; CAMCOG = Cambridge 
cognition examination; F = female; M = male; MMSE = Mini Mental state examination; N = number of subjects; na = not available; NPD = no patho-
logical diagnosis; PSND = poststroke non-demented; PSD = poststroke dementia; VaD = vascular dementia; WM = white matter.
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in order to confirm the position of blood vessels in the 
sections. Ultrathin sections were cut using a DDK Delaware 
diamond knife and placed onto 3.05  mm nickel 300 square 
mesh grids, which had been pre-treated with 10% nitric 
acid. OsO4 treated sections were used for morphological 
examination (57).
Immunofluorescence methods
Tissue sections were first treated with 0.1  mg/mL protease 
and then, incubated overnight at 4°C with primary antibod-
ies to anti-COL4 (C1926 Sigma) monoclonal antibody, anti-
PDGFR-β, (1:200 dilution, AF385, R&D Systems), αSMA 
(1:500 dilution, Clone 1A4, Dako) and glucose transporter-1 
(GLUT-1, 1:200, Thermo Scientific). Sections were washed 
with PBS and further incubated with donkey anti-goat con-
jugated Alexa Fluor 594 (1:1000, A11058, Thermo Fisher 
Scientific, Waltham, MA, USA) and rabbit anti-mouse Alexa 
Fluor 488 (1:1000, A11059, Thermo Fisher Scientific). 
Sections were then washed in PBS before mounting in 
Vectashield with DAPI (H-1200, Vector Laboratories). Images 
were captured using a Leica TCS SP2 (upright) and Zeiss 
Spinning Disk (Invert) confocal microscopes as described 
previously (15).
COL4 specific histochemistry to assess 
pericytes
How to reliably identify pericytes has been a key question 
in microvascular research. In view of the general absence 
of a single marker of pericytes for robust use in human 
tissues, we developed COL4 immunohistochemistry as a read-
ily applied method to determine densities of microvascular 
pericytes in disease and in experimental animals (Figures 1 
and 2). As described above, tissue sections were immunostained 
with well-characterised COL4 antibodies and then, counter-
stained with hematoxylin (Figure 1). Pericytes with a nucleus 
characteristically recognized as nodules or “bumps” or “cres-
cent” shaped cell bodies were counted manually along capil-
lary profiles from more than 2000 captured images. The 
total number of pericyte cell bodies were then determined 
for each case from 8 to 25 frames per case and then, a 
mean number was calculated per case. In total, we counted 
over 2100 pericytes involving 1450 images with each group 
comprising at least 10 cases. A pericyte (cell body) was 
counted only if  it had the characteristic shape and there 
was a clear nucleus within as identified by hematoxylin under 
×40 magnification. We were careful to count pericytes wrapped 
round COL4 on abluminal surface of the capillary only, 
unlike luminally localized endothelial cells (Figure 1A–K). 
In contrast to previous studies (44), we did not determine 
pericyte cell coverage because our intent was to assess poten-
tial change in pericyte nuclei as a more accurate measure 
of pericyte status in chronic disorders. Throughout, the 
histopathological analyses were performed blind to the opera-
tor. The inter-rater reliability in recognizing COL4 positive 
pericyte soma by two independent investigators (RD and 
JB) was more than 95% with the kappa score of 0.96.
Image acquisition and analysis of pericyte 
densities
Images of  capillary beds or regions of  interest (ROI) within 
the tissue sections were captured on a Zeiss Axioplan 2.0 
microscope and Image capture software (Infinity Capture 
V4.6.0, Lumenera Corporation), taking care to avoid large 
vessels including arterioles >20  µm external diameter 
(Figure 3D–I). Immunohistochemical staining was quantified 
using Image-Pro Plus (V.6.3; Media Cybernetics, Silver 
Spring, MD, USA). We assessed the percent area (% Area) 
for each case from at least 10 ROI images representing 
the vascular area stained with COL4 (as % COL4 Area) 
and to test the quality of  the immunoreactvities between 
individual sections and cases, we ascertained the integrated 
optical density (IOD). There were no significant differences 
in IOD values between disease and control samples. We 
also found there was a lack of  relationship between the 
immunohistochemical staining of  COL4 or PDGFR-β and 
length of  fixation, or post-mortem interval, between the 
groups. The percentage of  COL4 stained area (%) and 
COL4 stained area (mm2) were analyzed manually using 
the Image-Pro Plus Analyzer. COL4 stained area in mm2 
was derived using the equation 1% COL4 stained 
area=  8.0  ×  10−3  mm2.
For the values of pericyte numbers per COL4 area, we 
divided the numbers of cells by the COL4 area (mm2) in 
each image and calculated a mean value for each case from 
the number of images. To obtain pericyte soma per unit 
capillary length, we calculated the total length of capillaries 
per image and used that value as the denominator to obtain 
a mean value for each case. Taking into account that human 
brain capillaries are 5–9  µm in diameter, capillary length 
was determined from more than 2000 2D images as described 
previously (11,29).
Enzyme linked immunosorbent assays (ELISA)
Protein extracts of frozen tissue from the frontal WM for 
10–16 cases in each group were assayed to determine fibrino-
gen and PDGFR-β immunoreactivities. Homogenates of 
tissue were prepared essentially as described previously for 
the multiplex cytokine assays (14). Fibrinogen was deter-
mined using a sandwich ELISA (25). PDGFR-β was assayed 
as specified by the manufacturer (Human Total PDGFR 
beta DuoSet IC ELISA, DYC385, R&D Systems, 
Minneapolis, MN). For both proteins, the relative values 
were calculated and units expressed per mg protein.
Three vessel occlusion model and pericyte 
analysis in WM of nonhuman primates
Postmortem brain tissues were obtained from adult baboons 
(Papio Anubis) weighing 16–20  Kg (7–12  years old), housed 
at the Institute of Primate Research (IPR), National Museums 
of Kenya. The IPR internal review board of the National 
Museums granted ethical approval and permission for this 
entire study. As described previously (13), the animals were 
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subjected to permanent occlusion of both the internal carotid 
arteries and a left vertebral artery for survival periods of 
1, 3, 7, 14, 21 and 28  days, as well as sham operated 
animals (n  =  4–8 each group). We evaluated densities of 
capillary endothelium using H&E and COL4 immunohis-
tochemistry as described above, and the BBB leakage with 
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fibrinogen (1:2000 dilution, A0080, Dako, Cambridge, UK) 
(13). Pericytes in the deep WM were determined in coronal 
sections at the level of the frontal lobe in the same manner 
as described above in human brains. Percentage of fibrinogen 
stained area (%) in the WM was calculated to evaluate 
BBB leakage.
Statistical analyses
Data were analyzed using GraphPad Prism and SPSS (V19.0, 
IBM). Data were confirmed for normality using the Shapiro–
Wilk test. Differences between means of groups were first 
tested using one-way ANOVA followed by Tukey’s post hoc 
test or Kruskal–Wallis H test where appropriate. Linear 
correlations between PDGFR-β immunoreactivity and num-
ber of pericytes per COL4 area (mm2) or per unit capillary 
length and between fibrinogen and pericyte numbers per 
COL4 area (mm2) were performed using the Pearson’s cor-
relation, as described previously (16). Differences were con-
sidered significant with P-value less than 0.05 and data are 
presented as mean  ±  SEM.
RESULTS
Identification of pericytes in COL4 
immunostained capillaries
We had previously noted characteristic nodule-like “bumps” 
and “crescent” shaped cell features immunostained with 
COL4 that were contiguous with the basement membrane 
of microvessels but were evident as distinct entities and 
clearly different in size and flat features of luminal endothe-
lial cells (Figure 1). They occurred at irregular intervals in 
the microvascular network of both the cerebral cortex and 
WM. They were readily observed along lengths of capillary 
profiles (~5–9  µm diameter), particularly evident in thicker 
tissue sections (Figure 1A). They were negative for specific 
markers of the endothelium such as GLUT1 (Figure 1B). 
We double immunostained 10 frontal cortex tissue sections 
with antibodies to GLUT-1 and COL4 and in none of 
them was there an overlap between the two markers indi-
cating that COL4+ve cell bodies were not endothelial cells, 
consistent with our previous work (15). Upon double immu-
nostaining with various cellular markers, we confirmed the 
“bumps” to be pericytes and positive for PDGFR-β 
immunoreactivity (Figure 1C–F). They had similar profiles 
in both human and baboon WM, which was retrieved from 
the perfused brains (Figure 1G, cf. F and H). We also 
found they were positive for BMP4 immunoreactivity (Figure 
1E) but these were present only in a proportion of the 
capillary segments (52). Our observations also confirmed 
PDGFR-β immunoreactivity was largely associated with 
pericytes in capillaries and in the virtual absence of αSMA 
reactivity (0.1% in 50 capillary profiles). Upon electron 
microscopy of the post-mortem tissue, we further confirmed 
that the large sizes of pericyte cell bodies and their clear 
differential localization were not those of endothelial cells 
(Figure 1I–L). As there are pericytes in arterioles or pre-
capillaries, which also have more endothelial cells (Figure 
1M), we particularly concentrated on capillary pericytes 
(<10  µm diameter) associated with BBB.
Using immunofluorescence and confocal microscopy, we 
further confirmed and validated that the “bumps” and “cres-
cent” like cellular structures were pericyte somata (Figure 
2A–F). They were positive for PDGFR-β, delineated by 
COL4 immunoreactivity and contained nuclei (Figure 2G–J). 
We determined the cell somas were ~4–5  µm in diameter 
(cf. Figure 1H) and frequently observed with extended lon-
gitudinal and circumferential processes positive for PDGFR-β 
(eg, Figure 2F). Thus, the nodule-like structures on capil-
laries immunostained by COL4 were established as bona 
fide pericyte somata, which were reliably identified for quan-
tification. In parallel experiments, we found that antibodies 
to laminin, another basement membrane marker could be 
used to identify pericytes in this manner (data not shown).
In accord with our previous work on the gliovascular 
unit in the WM in different dementias (30), we focused on 
the frontal deep WM, which is most frequently afflicted by 
demyelination and cerebral SVD associated with the VaDs. 
Quantification of COL4 immunostained pericyte somata on 
capillaries free of any αSMA (Figure 3A–C) with clear nuclei 
in the deep WM in normal controls (Figure 3D–I) indicated 
that the overall mean (±SEM) densities of pericyte cell 
somas in young controls were estimated to be between 1.8 
and 2 ±0.1  mm capillary length. We did not detect the 
significant differences in pericyte numbers between young 
and older controls although the mean in older controls was 
~15% less (P  >  0.05, n  =  9–10, 200–320 pericytes).
We next quantified pericyte cell bodies within WM capil-
laries across several dementias characterized by variable 
degrees of demyelination and vascular pathology (Figure 4). 
Figure 1. Cerebral capillaries with pericytes in the frontal cortex and 
WM of aging subjects. A–F. Pericytes evident as “bumps” or “crescent” 
shaped cells in the capillary network immunostained with antibodies to 
COL4 (A, G, H, I, J and K), GLUT1 (blue-black) and COL4 (brown) (B), 
PDGFR-β (brown) and COL4 (blue/gray) (C), PDGFR-β (D, F) and BMP4 
(E). Arrows show location of the pericyte cell bodies along the capillaries. 
G–K. Pericyte soma (black arrows in G, H, J and K) and endothelial cell 
(white arrowhead in G and I) and other types of cells including 
erythrocytes observed within the lumen (white arrowhead in J and K) in 
the frontal WM capillaries of the Baboon (G–I) and human (J and K). 
L,M. Transmission electron microscope images show pericyte cell body 
(P) on a WM capillary (L) and precapillary/small arteriole (M) in cross-
section from 65-year-old male subject. The marked differential localization 
between the pericyte and endothelial cell (EC) and the lumen with an 
erythrocyte (R for red blood cell) can be noted. L–M also assure 
assessment of non-capillary pericytes or EC or smooth muscle cell 
nuclei were not included in the pericyte counts. Images in A and B were 
from 20 µm thick sections, whereas those from C to I were from 10 µm 
sections. Length density of frontal cortical capillaries (A) was greater 
than WM (B). Magnification bars: A, G = 50 µm; C, F = 30 µm; B, D, 
E = 20 µm; H, I, J, K = 10 µm; L = 1 µm; M = 5 µm.
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In tandem with the WM pathology scores in these cases 
(Table 1), we first ascertained the extent of BBB leakage 
in the deep WM of subjects with the dementias. Using 
fibrinogen as a surrogate marker for BBB damage, we found 
that the specific activity of this extravascular protein was 
increased in PSD, VaD, Mixed and AD subjects compared 
to aging controls. However, as expected fibrinogen was also 
increased in PSND subjects since they exhibit similar vascular 
pathology to PSD subjects (Figure 4A; Table 1). We found 
that irrespective of the method used for calculation that is, 
numbers of pericyte cell bodies per COL4 area (mm2) or 
cell densities per mm capillary length, pericytes were variably 
decreased by 35%–45% in the frontal WM across all the 
dementias (Figure 4B,C). Remarkably, VaD subjects were 
Figure 2. Pericyte soma on WM capillaries demonstrated by 
immunofluorescence. A–F. PDGFR-β (red) and COL4 (green) 
immunofluorescence staining with nuclei (DAPI) (blue). A,B. Low- and 
high-power images showing capillary segments (arrowheads) with 
overlapping PDGFR-β (red), COL4 (green) and DAPI (blue). C. Same 
vessel segment as B with PDGFR-β (red) and COL4 (green); D. COL4 
(green) and DAPI (blue); E. PDGFR-β (red) and DAPI (blue). F. Another 
capillary segment with PDGFR-β (red), COL4 (green) and DAPI (blue) 
clearly showing pericyte cell body. G–J. Images taken by a confocal 
microscope showing pericyte cell bodies (arrows) with nuclear stain 
(DAPI). Capillaries and pericyte processes are revealed by COL4 and 
PDGFR-β (red) immunoreactivities. Magnification bars: A  =  50  µm, F, 
J = 10 µm.
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the most affected (Figure 4B). More importantly though, 
we noted that pericyte numbers in the PSD group were 
significantly reduced compared to similar age PSND subjects 
(P  <  0.001) and older controls (P  <  0.001) (Figure 4B). 
However, this was not necessarily accompanied by a reduc-
tion in WM capillary length density between PSD and PSND 
subjects (29) or significant alteration in the % area covered 
by COL4 immunoreactivity. The % areas with COL4 immu-
nostained capillary profiles were not significantly different 
between controls, PSND and PSD or VaD groups (P > 0.05). 
Despite the presence of similar burdens of vascular pathol-
ogy in the PSD and PSND groups, density of capillary 
pericytes specifically separated poststroke decliners from stable 
subjects. We also found that fibrinogen reactivity was nega-
tively but weakly correlated with pericyte soma numbers 
per COL4 area (r  =  −0.3; P  =  0.057) (Figure 4D).
To demonstrate the differential effects in pericytes identi-
fied morphologically by COL4 plus the nuclear stain, we 
next concentrated on comparisons between PSD and PSND 
subjects. We performed PDGFR-β immunoassays (ELISA) 
in available extracts from WM tissue samples adjacent to 
tissue sections that were used for the morphological analysis. 
While we found there was a clear trend in PDGFR-β 
immunoreactivity in the order: old controls >PSND > PSD 
(Figure 5A), the mean values for PDGFR-β assessed by 
ELISA did not reach statistical significance (P  >  0.05). 
PDGFR-β immunoreactivity was reduced by 30%–40% in 
PSD and PSND subjects compared to controls (Figure 5B). 
However, we observed a strong correlation between numbers 
of pericyte somata and PDGFR-β reactivities in matched 
samples (r  =  0.6, P  =  0.007) (Figure 5C). These results 
confirmed the relationship between pericyte cell numbers 
and PDGFR-β reactivity in the WM and indicated trends 
in lower expression of PDGFR-β in PSD subjects.
In further experiments, we tested the hypothesis if  
fibrinogen leakage was specifically associated with changes 
in pericytes. Using WM tissues from a previously described 
baboon model of  cerebral hypoperfusion, we found that 
pericytes numbers determined using the same methods 
above were reduced at 14  days after 3 vessels occlusion 
(3VO) (Figure 6B), whereas mean vascular density as 
assessed by COL4 immunoreactivities were not altered over 
the survival period (Figure 6A). This was concomitant 
with peak of  fibrinogen reactivity in the WM tissues 
(Figure 6B). All original data presented in this article are 
available for review.
Figure 3. Quantification methods used for determining density of 
pericytes associated with capillaries. A–C. Immunofluorescent staining 
of WM capillaries and arterioles. A. COL4 (green). B. α-SMA (red). C. 
merged image of A and B. Quantification of pericytes was performed on 
COL4-positive but α-SMA-negative capillary profiles. Each inset showing 
an arteriole double-positive for COL4 and α-SMA (white arrow) at higher 
magnification. D–I. Pericyte cell bodies revealed by COL4 immunostaining 
and hematoxylin nuclear counterstain as crescent shapes or as bumps 
on capillaries of the WM. Pericytes cell bodies are evident in longitudinal 
(G) and transverse profiles (H) as well as at intersections (I) of capillaries. 
G–I. Each inset showing a pericyte (arrow) at higher power. Magnification 
bars: C, F = 200 µm; I = 50 µm.
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Figure 4. Quantification of WM pericytes in different dementias 
compared to normal aging controls. A. Fibrinogen reactivity in frontal 
WM in control, PSND and different dementia groups. Fibrinogen 
reactivity measured by ELISA in WM extracts was increased in PSND 
and all the dementia groups compared to controls (*P  <  0.05; 
**P  <  0.01). B,C. Box plots show pericyte numbers per COL4 area 
(mm2) (B) and per unit (mm) capillary length (C). Pericyte numbers were 
decreased in PSD compared to PSND subjects (***P  <  0.001). They 
were also decreased in all the dementia types compared to controls and 
young controls. (***P < 0.001, one-way ANOVA, n = 8–12 cases). Data 
generated from counts of pericytes per case comprising 110 to 385 cells 
per each group derived from 82 to 382 separate images. D. Correlation 
of fibrinogen reactivity (% RV, relative values) with pericyte number per 
COL4 area (mm2) (Pearson’s r = −0.3, P = 0.057). Demographic details 
of the subjects are given in Table 1.
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Figure 5. Quantification of PDGFR-β reactivity by ELISA in the frontal 
WM. A,B. Box plots show relative PDGFR-β reactivity in extracts of the 
WM from PSD subjects compared to PSND and normal controls. A. 
Plots show PDGFR-β value (pg/mg protein). B. Plots represent PDGFR-β 
ratio standardised to control (control = 1). C. Correlation of PDGFR-β 
reactivity by ELISA and pericyte number per COL4 area in frontal WM. 
PDGFR-β detected by ELISA was correlated with pericyte number per 
COL4 area (Pearson’s r = 0.6, P = 0.007).
Figure 6. Integrity of the BBB and pericyte numbers in the frontal WM 
in a nonhuman primate model of cerebral hypoperfusion. A. Box plots 
showing mean vascular density (% COL4 stained area) in the frontal 
WM of adult baboons subjected to 3VO. Each time point represents 
mean of n = 4–8 animals and the results were computed from both 
hemispheres. There were no differences between the right and left 
sides. Microvascular density was not changed after 3VO compared to 
Sham operated animals (P > 0.05). B. Quantification of pericytes density 
and fibrinogen reactivity in the frontal WM of adult baboons subjected 
to 3VO. There was a high variation in fibrinogen immunoreactivity over 
survival time (P < 0.01). Fibrinogen immunoreactivity was the highest at 
14 days after 3VO compared to Sham, 1 and 28 days after 3VO groups 
(*P  <  0.05), concomitant with relatively lower pericyte density at 
14 days.
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DISCUSSION
In this study, we explored actual numbers of pericytes with 
a nucleus on capillaries rather than coverage of pericyte 
processes in the deep WM across several dementias with 
vascular pathology. Using conventional immunohistochemical 
and immunofluorescence methods, we first demonstrated that 
pericyte somata are contiguous with COL4 immunostained 
capillary network and microvascular profiles. We then deter-
mined numbers of pericytes with the requirement that each 
cell soma should contain a nucleus to be considered as a 
bona fide capillary pericyte. We manually only counted 
pericyte bodies with clear visible nuclei, which were always 
located abluminally and counted at high power magnifica-
tion as typical bumps or protruded bodies into the paren-
chyma. We are confident these were not mistaken for 
protruding nucleated endothelial cells because previously in 
assessing some 0.7  million profiles of capillaries (29), we 
only observed occasional luminal blebs arising from endothe-
lial cells. Unlike endothelial cells, we also found pericyte 
cells bodies were GLUT1 negative but positive for COL4 
or for PDGFR-β (15). Furthermore, we noted endothelial 
cells were few times greater in number than the pericyte 
cell bodies. This is consistent with greater densities of FLI1 
nuclear marker used to track retinal endothelial cells, which 
were 20–30 per mm capillary length (55). Irrespective, as a 
caveat it is not unlikely that we have occasionally included 
endothelial cell nuclei in the manual counts (43). However, 
overall the current described criteria and our previous obser-
vations (15), it is clearly possible to distinguish differences 
in the morphology and location of nuclei of pericytes and 
endothelial cells (43).
Consistent with the finding that COL4 is a viable marker 
to identify pericyte soma, we had previously reported a 
strong relationship between COL4 and PDGFR-β immu-
noreactivities but not GLUT1 and PDGFR-β in WM (15). 
Although pericyte numbers were determined using 2D imag-
ing analysis rather than 3D stereology, we are confident 
that the estimated numbers are close to the actual because 
in our previous study (11), we did not find substantial 
differences in capillary length determination using the two 
quantitative morphological approaches. Our findings indicate 
that pericyte cell density was approximately 2 per mm 
capillary length in the WM. This number was slightly higher 
in the overlying frontal cortex and was estimated to be 
3–5 per mm capillary length (22). Given these numbers 
and knowing the approximate length density of  capillaries 
in the human brain is 650  km (6), we estimate the range 
of  numbers of  capillary pericytes at any one time in normal 
aging human brain is ~0.4–1.0  billion. This may be an 
over estimate and does not include pericytes and pericyte-
like cells that regulate the circulation in larger vessels 
including arterioles and penetrating arteries (15,21). 
Consistent with these observations, Berthiaume et al (8) 
indicate ~2–3 pericyte nuclei per mm of mid-capillary region 
in the mouse cortex. Our study also demonstrates a reli-
able morphological method to estimate numbers of  nucle-
ated pericytes in COL4 or similar markers such as laminin 
that capture components of  the basement membrane. The 
pericyte cell bodies with a nucleus protected by a visible 
COL4 positive membrane suggests viable cells that may 
not necessarily reflect the same as when pericyte coverage 
is used to determine pericyte status. However, our observa-
tions are consistent with previous studies (44). We could 
not reliably assess pericyte coverage with antibodies to 
PDGFR-β in human post-mortem tissue. We attempted 
immunostaining of  large numbers of  sections with PDGFR-β 
antibodies, but it was never as consistent or robust as 
COL4 immunohistochemistry. However, we were able to 
use immunofluorescence to verify that COL4 stained peri-
cytes are bona fide pericyte soma.
Although an earlier ultrastructural study using neurosurgi-
cal biopsies (51) showed that pericyte cell area in capillaries 
of the WM underlying the frontal and temporal cortex was 
substantially reduced (>50%) in 80 year olds compared to 
20  years olds, we did not detect a significant difference in 
our younger and older controls. However, the loss of peri-
cytes with age implies decreased ability of the BBB to 
compensate for transient leaks in the elderly. In the study 
by Stewart and colleagues (51), however, it was noteworthy 
pericyte cell area in human brain was 2–3 times lower in 
the WM compared to the gray matter. By proxy, this cor-
roborates our observations on the differential in pericyte 
cell nuclei between frontal WM and frontal cortex capillaries 
(22) (RD, YH, RK unpublished observations).
The most important finding was that capillary pericytes 
were reduced in the WM in PSD and VaD subjects and 
those with other common dementias including Mixed and 
AD. Given significant SVD pathology associated with VaD 
and Mixed dementia (18), it is not surprising that pericytes 
were decreased in these old age dementias. However, the 
remarkable observation was that pericytes were specifically 
impaired or degenerated in poststroke survivors who developed 
dementia (PSD) compared those who did not (poststroke no 
dementia; PSND). This cellular alteration occurred in parallel 
to fibrinogen leakage and apparent in the deep WM, which 
is affected by demyelination and SVD pathology in the aging-
associated dementias. Previous studies have suggested that 
while ablation of a single pericyte soma in rodents does not 
affect focal BBB function (8), the absence of pericytes induces 
microvessel leakage and microvessel regression (44, 54). 
Fibrinogen leakage related toxicity has been implicated in 
the loss or degeneration of pericytes (40). Our results in the 
3VO nonhuman primates, where we could also completely 
control any post-mortem artifacts supports such a link between 
fibrinogen leakage and pericyte degeneration. However, it is 
not unlikely that there is specific disruption of the gliovas-
cular unit (30) particularly associated with frontal WMH 
volumes (13). We have shown that this is characterized by 
widespread astrocytic clasmatodendrosis involving removal of 
astrocyte end-feet and aquaporin IV positive water channel 
protein from the capillary walls in the deep WM of PSD 
(13) as well as CADASIL patients (27).
Our observations in AD on reduced pericyte numbers in 
the WM are remarkably consistent with pericyte coverage 
measured by PDGFR-β immunoreactivity in WM of the 
prefrontal cortex (44). They found 50% loss of pericyte cov-
erage associated with accumulation of extravascular fibrinogen 
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in the subcortical WM of AD subjects. They suggested that 
pericytes instigate WM disease associated with SVD consistent 
with the dynamic structural remodeling in disease (9). However, 
our observations are somewhat at odds with the study of 
Miners et al (42) in which PDGFR-β reactivity was assayed 
by ELISA. They reported that although there was fibrinogen 
leakage and reduced oxygenation, as assessed by the myelin-
associated glycoprotein: proteolipid protein-1 ratio, in the 
underlying WM of the precuneus in the parietal lobe, PDGFR-β 
reactivity was not significantly changed in AD subjects. This 
may indicate there is a lack of change in actual pericytes 
in WM of the parietal lobe in AD. Previous studies (42, 
47) have further suggested that amyloid β is likely directly 
toxic to pericytes. Our results are not compatible with the 
role of soluble or insoluble amyloid β in pericyte degenera-
tion in the frontal WM across the VaDs and AD. In addi-
tion, we have previously reported that both PSD and PSND 
groups had similar amyloid β load (1). Our results argue for 
a different mechanism in specific pericyte loss associated with 
WM degeneration that may primarily relate to BBB damage 
(44). In prior (42, 44) and our studies here, we found that 
fibrinogen reactivity was increased in the WM indicating 
degrees of WM BBB damage in different dementias. However, 
fibrinogen was also increased in PSND as it was in PSD 
subjects. This was not surprising given that PSND group 
exhibited high degree of WM pathology. It is plausible that 
in PSD subjects there is more advanced disruption of other 
cellular elements together that progressively reaches a certain 
threshold to disrupt WM fibers and precipitate dementia.
In view of the unavailability of robust markers of pericytes 
for use in human tissues (50), we propose that COL4 could 
be readily applied to determine cell densities of microvascular 
pericytes in disease and in experimental animals. Previous 
studies have used several markers to label pericytes, such as 
PDGFR-β, NG2, BMP4, αSMA, endosialin, angiopoietin-1 
(Ang-1), RGS5 and desmin (4, 39, 56). However, there is 
no single marker specific for pericytes; a unique molecular 
signature of pericytes has not yet been uncovered. PDGFR-β 
immunoreactivity is the most used pericyte marker but it is 
also apparent in neurons, myofibroblasts, fibroblasts, vascular 
smooth muscle cells and endothelial precursor cells (3, 19). 
Unlike in cerebral cortex, we found PDGFR-β immunore-
activity in the human WM to be mostly but not solely 
associated with WM pericytes. This finding was consistent 
with the correlation between pericyte numbers per COL4 
area in mm2 and PDGFR-β immunoreactivity that also veri-
fied that the loss of pericytes in PSD was related to decreased 
PDGFR-β. The lower expression of PDGFR-β immunore-
activity in PSND may be explained by increasing atrophy 
of pericyte cell processes that had not yet lost their nuclei.
The loss or degradation of pericytes could occur because 
of hemodynamic changes and greater degree of endothelial 
damage at the molecular level that progresses in subjects 
who develop cognitive impairment or dementia (46). We 
previously found that a noninvasive procedure such as long-
term bilateral carotid artery stenosis causing cerebral hypop-
erfusion in the WM triggers disruption of the gliovascular 
unit including severe clasmatodendrosis likely because of 
hemodynamic changes in the circulation (28). It is not 
unlikely that a vicious cycle is set up whereby detachment 
of perivascular cells such as pericytes than are exposed to 
blood-derived proteins which are then create a toxic envi-
ronment on the abluminal side of the capillary network.
Our study has a few limitations. First, we did not assess 
pericyte numbers in the WM of other lobes of the brain, 
for example in previously reported regions such as that 
underlying the precuneus. We surmised that quantification 
of other regions required a monumental effort that may 
not reveal different results given that WM changes associ-
ated with SVD and possible fibrinogen leakage may have 
similar outcomes. Second, we used straightforward 2D meas-
urements rather than 3D stereology in the quantification 
of pericyte numbers. We reasoned that it was unnecessary 
since we had previously shown that the qualitative changes 
described using 2D measurements are similar to those 
obtained with 3D stereology (11), which is cumbersome for 
large numbers of samples. While further labor-intensive work 
could provide reveal precise numbers and turnover of peri-
cytes, we do not believe our estimates of pericyte numbers 
are grossly over. The pertinent finding here is that capillary 
pericyte somata were fewer in subjects who developed demen-
tia. Third, the availability of more specific markers of peri-
cytes would also have been useful to verify our findings 
on the mechanics of pericyte cell impairment or turnover 
and determine if  PDGFR-β is decreased intracellularly prior 
to complete degeneration in the persistently hypoxic state 
within the deep WM in aging-related dementias (23).
In summary, using a relatively simple morphometric method, 
we found that numbers of capillary pericytes in the WM 
were reduced across all common dementias but particularly 
in individuals who develop dementia after stroke injury. 
Pericyte cell loss is likely associated with disintegration of 
the gliovascular unit of the WM that impairs BBB function. 
These changes in the deep WM are remote from any direct 
local tissue injury and consistent with the notion that degen-
erative processes in the WM are instigated by perfusion 
disturbances from the circulation. Our observations suggest 
pericytes as components of the gliovascular unit of the WM 
are an important target for therapeutic interventions.
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